# Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

> **NCT00380250** · PHASE3 · COMPLETED · sponsor: **Sucampo Pharma Americas, LLC** · enrollment: 590 (actual)

## Conditions studied

- Irritable Bowel Syndrome With Constipation

## Interventions

- **DRUG:** Lubiprostone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00380250
- **Lead sponsor:** Sucampo Pharma Americas, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** —
- **Final completion:** 2006-07
- **Target enrollment:** 590 (ACTUAL)
- **Last updated:** 2019-11-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00380250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00380250, "Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00380250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*